For advanced GC with human epidermal growth factor receptor 2 (HER2) positive, the combination of trastuzumab plus chemotherapy has become the first-line treatment option, based on the results of the Trastuzumab for Gastric Cancer (ToGA) study (2). This evidence concerns the gene ERBB2 and gastric cancer.